Cognitive impairment in patients with clinically isolated syndrome

Anhoque, Carolina Fiorin; Neto, Laurentino Biccas; Domingues, Simone Cristina Aires; Teixeira, Antônio Lúcio; Domingues, Renan Barros

doi:10.1590/s1980-57642012dn06040011

Cited by 9 publications

(3 citation statements)

References 22 publications

(24 reference statements)

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Over a mean follow-up period of about 3 years, the annual PBVC values were significantly lower in CIS patients when compared to the MS cohort [93]. Neuropsychological impairment, affecting mental speed processing, episodic memory, executive functions and attention, may be present in up to 50% of patients with MS [94] and has been found to occur early in the disease course [95]. Changes of brain parenchymal fraction (BPF) have been shown to predict cognitive impairment over 2 years in patients with early MS [96].…”

Section: Clinical Correlates Of Brain Atrophymentioning

confidence: 96%

Brain atrophy in multiple sclerosis: mechanisms, clinical relevance and treatment options

Andravizou

Dardiotis

Artemiadis

et al. 2019

Autoimmun Highlights

112

View full text Add to dashboard Cite

Multiple sclerosis (MS) is an immune-mediated disease of the central nervous system characterized by focal or diffuse inflammation, demyelination, axonal loss and neurodegeneration. Brain atrophy can be seen in the earliest stages of MS, progresses faster compared to healthy adults, and is a reliable predictor of future physical and cognitive disability. In addition, it is widely accepted to be a valid, sensitive and reproducible measure of neurodegeneration in MS. Reducing the rate of brain atrophy has only recently been incorporated as a critical endpoint into the clinical trials of new or emerging disease modifying drugs (DMDs) in MS. With the advent of easily accessible neuroimaging softwares along with the accumulating evidence, clinicians may be able to use brain atrophy measures in their everyday clinical practice to monitor disease course and response to DMDs. In this review, we will describe the different mechanisms contributing to brain atrophy, their clinical relevance on disease presentation and course and the effect of current or emergent DMDs on brain atrophy and neuroprotection. which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made.

show abstract

Section: Clinical Correlates Of Brain Atrophymentioning

confidence: 96%

Brain atrophy in multiple sclerosis: mechanisms, clinical relevance and treatment options

Andravizou

Dardiotis

Artemiadis

et al. 2019

Autoimmun Highlights

112

View full text Add to dashboard Cite

show abstract

“…The lower frequency of cognitive impairment in the present study compared with previous studies may be due to use of the 2010 McDonald diagnostic criteria, which allow the diagnosis of RRMS to be made earlier, possibly creating lead time bias; thus, the present population may be more in keeping with previous studies on clinically isolated syndrome, the clinical precursor to MS. McIntosh-Michaelis et al 25 noted that cognitive impairment often occurred very early in the course of MS. In a systematic review of clinically isolated syndrome and cognitive impairment, Anhoque et al 26 also found evidence of cognitive impairment; the most frequently affected domains were visuospatial skills, executive function, and processing. Similar to the present results, this study directs attention to the levels of dysfunction that may exist early in the disease course.…”

Section: Practice Pointsmentioning

confidence: 99%

Short Report: Prevalence of Cognitive Impairment in Newly Diagnosed Relapsing-Remitting Multiple Sclerosis

DiGiuseppe¹,

Blair²,

Morrow³

2018

International Journal of MS Care

View full text Add to dashboard Cite

Background:Cognitive impairment is common in multiple sclerosis (MS) and can manifest early in the disease process, sometimes as early as the first demyelinating event. However, the frequency of cognitive impairment in a newly diagnosed MS population has not been evaluated comprehensively in a clinical population. We sought to examine the prevalence of cognitive impairment in relapsing-remitting MS (RRMS) within a year of diagnosis in a clinic where cognitive testing at diagnosis is part of routine practice.

show abstract

“…The progressive forms of MS are linked to a more pronounced and frequent cognitive deficit compared to relapsing-remitting multiple sclerosis (RRMS) [20]. However, mental disability was also observed in the early stages of the disorder, even in clinically and radiologically isolated syndromes (RISs) [21]. The definition of early-stage MS remains intensely discussed within the literature, as definitions vary among studies.…”

Section: Epidemiological Data Explaining the Burden Of Cognitive Impa...mentioning

confidence: 99%

Risk Factors for Cognitive Impairment in Multiple Sclerosis Patients

Schreiner,

Mihoc,

Grigore

et al. 2024

Sclerosis

View full text Add to dashboard Cite

Cognitive impairment is one of the most significant burdens among the many neurological complaints in multiple sclerosis patients. Cognitive deficits negatively impact these patients’ quality of life, leading to partial or total loss of several mental functions, such as learning, memory, perception, or problem-solving. While the precise mechanisms involved in the onset and evolution of cognitive decline remain unknown, several risk factors have been associated with intellectual disability. With increasing data on this topic in recent years, the main aim of this review is to summarize the most relevant risk factors correlated with cognitive impairment in multiple sclerosis patients. Firstly, the authors demonstrate the importance of mental disability based on epidemiological data from multiple sclerosis patient cohorts. Subsequently, the intensely debated major risk factors for cognitive decline are discussed, with brief insights into the pathophysiology and possible underlying mechanisms. Finally, the authors describe the impact of medication on cognitive impairment in multiple sclerosis patients, highlighting the main research directions for future studies.

show abstract

Cognitive impairment in patients with clinically isolated syndrome

Cited by 9 publications

References 22 publications

Brain atrophy in multiple sclerosis: mechanisms, clinical relevance and treatment options

Brain atrophy in multiple sclerosis: mechanisms, clinical relevance and treatment options

Short Report: Prevalence of Cognitive Impairment in Newly Diagnosed Relapsing-Remitting Multiple Sclerosis

Risk Factors for Cognitive Impairment in Multiple Sclerosis Patients

Contact Info

Product

Resources

About